Preclinical studies of PF-04849285, an interferon-α8 fusion protein for the treatment of HCV

Antiviral Therapy

Volumn 17, Issue 5, 2012, Pages 869-881

  Flores, M Victoria ^a   Hickling, Timothy P ^a   Sreckovic, Sasha ^a   Fidock, Mark D ^a   Horscroft, Nigel ^a   Katragadda, Madan ^b   Savic, Boris ^a   Rawal, Jaiessh ^a   Delpuech Adams, Oona E ^a   Robas, Nicola ^a   Corey, Thomas ^a   Nelms, Linda ^b   Lawton, Michael ^b   Marcek, John ^b   Stubbs, Makeida ^b   Westby, Michael ^a   Ciaramella, Giuseppe ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2',5' OLIGOADENYLATE SYNTHETASE; ALPHA INTERFERON DERIVATIVE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERFERON RECEPTOR; INTERLEUKIN 6; PEGINTERFERON ALPHA2A; PF 04849285; PF 0484985; RECOMBINANT ALPHA2A INTERFERON; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIPROLIFERATIVE ACTIVITY; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG POTENCY; ENCEPHALOMYOCARDITIS VIRUS; EX VIVO STUDY; FEMALE; HAPLORHINI; HEPATITIS C; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; SURFACE PLASMON RESONANCE; TOXICOKINETICS;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; DRUG EVALUATION, PRECLINICAL; ENCEPHALOMYOCARDITIS VIRUS; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON-ALPHA; MACACA FASCICULARIS; MALE; RECEPTORS, INTERFERON; RECOMBINANT FUSION PROTEINS; RECOMBINANT PROTEINS; TREATMENT OUTCOME; VIRUS REPLICATION;

EID: 84865730652     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP2099     Document Type: Article

References (38)

1. Nelson DR, Rustgi V, Balan V, et al. Safety and antiviral activity of albinterferon alfa-2b in prior interferon non responders with chronic hepatitis C. Clin Gastroenterol Hepatol 2009; 7:212-218.
2. Zeuzem S, Yoshida EM, Benhamou Y, et al. Albinterferon alfa-2b dosed every two or four weeks in interferon-naive patients with genotype 1 chronic hepatitis C. Hepatology 2008; 48:407-417.
3. Nelson DR, Benhamou Y, Chuang WL, et al. Albinterferon alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 2 or 3. Gastroenterology 2010; 139:1267-1276.
4. Zeuzem S, Sulkowski M, Lawitz E, et al. Efficacy and safety of albinterferon alpha-2B in combination with ribavirin in treatment-naive, chronic hepatitis C genotype 1 (CHC G1) patients. J Hepatol 2009; 50 Suppl 1:S377.
5. Hilkens CMU, Schlaak JF, Kerr IM. Differential responses to IFN-alpha subtypes in human T cells and dendritic cells. J Immunol 2003; 171:5255-5263.
6. Evinger M, Rubinstein M, Pestka S. Antiproliferative and antiviral activities of human leukocyte interferons. Arch Biochem Biophys 1981; 210:319-329.
7. Fish EN, Banerjee K, Stebbing N. Human leukocyte interferon subtypes have different antiproliferative and antiviral activities on human cells. Biochem Biophys Res Commun 1983; 112:537-546.
8. van Pesch V, Lanaya H, Renauld J-C, et al. Characterization of the murine alpha interferon gene family. J Virol 2004; 78:8219-8228.
9. Szubin R, Chang WL, Greasby T, et al. Rigid interferon-alpha subtype responses of human plasmacytoid dendritic cells. J Interferon Cytokine Res 2008; 28:749-763.
10. Aguet M, Grobke M, Dreiding P. Various human interferon alpha subclasses cross-react with common receptors: the binding affinities correlate with their specific biological activities. Virology 1984; 132:211-216.
11. Meister A, Uze G, Mogensen KE, et al. Biological activities and receptor binding of two human recombinant interferons and their hybrids. J Gen Virol 1986; 67:1633-1643.
12. Piehler J, Schreiber G. Biophysical analysis of the human type I interferon receptor ifnar2 expressed in E. coli with interferon alpha2. J Mol Biol 1999; 289:57-67.
13. Heathcote J. Consensus interferon: a novel interferon for the treatment of hepatitis C. J Viral Hepat 1998; 5:13-18.
14. Foster GR, Rodrigues O, Ghouze F, et al. Different relative activities of human cell-derived interferon-alpha subtypes: IFN-alpha 8 has very high antiviral potency. J Interferon Cytokine Res 1996; 16:1027-1033.
15. Koyama T, Sakamoto N, Tanabe Y, et al. Divergent activities of interferon-alpha subtypes against intracellular hepatitis C virus replication. Hepatol Res 2006; 34:41-49.
16. Yamaoka T, Kojima S, Ichi S, et al. Biologic and binding activities of IFN-alpha subtypes in ACHN human renal cell carcinoma cells and Daudi Burkitt's lymphoma cells. J Interferon Cytokine Res 1999; 19:1343-1349.
17. Brideau-Andersen AD, Huang X, Chang Sun S-C, et al. Directed evolution of gene-shuffled IFN-alpha molecules with activity profiles tailored for treatment of chronic viral diseases. Proc Natl Acad Sci U S A 2007; 104:8269-8274.
18. Yamamoto K, Taniai M, Torigoe K, et al. Creation of interferon-α8 mutants with amino acid substitutions against interferon-α receptor-2 binding sites using phage display system and evaluation of their biologic properties. J Interferon Cytokine Res 2009; 29:161-170.
19. Ciaramella G, Flores MV, Horscroft NJ, Katragadda M, Wu J, inventors; Pfizer Limited, assignee. Fusion protein, WO 064758. 2011 June 3.
20. Armour KL, Clark MR, Hadley AG, et al. Recombinant human IgG molecules lacking Fc-gamma receptor I binding and monocyte triggering activities. Eur J Immunol 1999; 29:2613-2624.
21. Lata S, Piehler J. Stable and functional immobilization of histidine-tagged proteins via multivalent chelator head-groups on a molecular poly(ethylene glycol) brush. Anal Chem 2005; 77:1096-1105.
22. Lata S, Gavutis M, Piehler J. Monitoring the dynamics of ligand-receptor complexes on model membranes. J Am Chem Soc 2006; 128:6-7.
23. Lamken P, Lata S, Gavutis M, et al. Ligand-induced assembling of the type I interferon receptor on supported lipid bilayers. J Mol Biol 2004; 341:303-318.
24. Kalie E, Jaitin DA, Podoplelova Y, et al. The stability of the ternary interferon-receptor complex rather than the affinity to the individual subunits dictates differential biological activities. J Biol Chem 2008; 283:32925-32936.
25. Immune epitope database and analysis resource. T cell epitope prediction tools. (Updated 7 August 2009. Accessed 23 September 2008.) Available from http://tools.immuneepitope.org/main/html/tcell-tools.html
26. Familletti PC, Rubinstein S, Pestka S. Assay for interferon: a convenient and rapid cytopathic effect inhibition assay for interferon. In Pestka S (Editor). Methods in Enzymology. Vol. 78. New York: Harcourt 1981; pp. 387-394.
27. Lohmann V, Körner F, Koch J, et al. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999; 285:110-113.
28. Pfeffer LM, Dinarello CA, Herberman RB, et al. Biological properties of recombinant α-interferons: 40th anniversary of the discovery of interferons. Cancer Res 1998; 58:2489-2499.
29. Pestka S, Krause CD, Walter MR. Interferons, interferon-like cytokines, and their receptors. Immunol Rev 2004; 202:8-32.
30. Jaitin DA, Roisman LC, Jaks E, et al. Inquiring into the differential action of interferons (IFNs): an IFN-alpha2 mutant with enhanced affinity to IFNAR1 is functionally similar to IFN-beta. Mol Cell Biol 2006; 26:1888-1897.
31. Goodbourn S, Didcock L, Randall RE. Interferons: cell signalling, immune modulation, antiviral responses and virus countermeasures. J Gen Virol 2000; 81:2341-2364.
32. Trown PW, Wills RJ, Kamm JJ. The preclinical development of Roferon-A. Cancer 1986; 57:1648-1656.
33. Osborn BL, Olsen HS, Nardelli B, et al. Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferon-alpha fusion protein in cynomolgus monkeys. J Pharmacol Exp Ther 2002; 303:540-548.
34. Food and Drug Administration. Toxicologist's review, BLA 99-1488/103949. (Updated 19 December 2000. Accessed 27 September 2008.) Available from http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/ HowDrugsareDevelopedandApproved/ApprovalApplications/ TherapeuticBiologicApplications/ucm094485.pdf
35. Subramanian GM, Fiscella M, Lamousé-Smith A, et al. Albinterferon alpha2b: a genetic fusion protein for the treatment of chronic hepatitis C. Nat Biotechnol 2007; 25:1411-1419.
36. Huston JS, Tai MS, McCartney J, et al. Antigen recognition and targeted delivery by the single-chain Fv. Cell Biophys 1993; 22:189-224.
37. Stebbings R, Findlay L, Edwards C, et al. 'Cytokine storm' in the Phase I trial of monoclonal antibody TGN1412: better understanding the causes to improve preclinical testing of immunotherapeutics. J Immunol 2007; 179:3325-3331.
38. Lange CM, Sarrazin C, Zeuzem S. Review article: specifically targeted anti-viral therapy for hepatitis C - a new era in therapy. Aliment Pharmacol Ther 2010; 32:14-28.